Genflow Biosciences, KEFI Gold and Copper, Valereum, Seeing Machines, Arecor Therapeutics, S&U

Group 1 - Genflow Biosciences Ltd is reporting positive early results from its clinical trial on aged dogs, with all treatment groups outperforming the control in muscle mass and quality of life, and no safety issues reported [1] - KEFI Gold and Copper PLC has secured full project financing of US$340 million for the Tulu Kapi project in Ethiopia, allowing for full mobilization at the site while minimizing equity dilution [2] - Valereum PLC has partnered with RWA.io to bridge traditional finance and digital assets, focusing on creating a toolkit for easier trading of tokenized products [3] - Seeing Machines Ltd has exceeded minimum volume guarantees in Q2, with expectations of reaching cash flow breakeven soon as automotive royalties increase [3] - Arecor Therapeutics PLC is advancing its ultra-rapid-acting insulin and preparing for a major phase II study, with a cash runway extending into 2027 [4] - S&U PLC is experiencing a significant recovery in confidence, anticipating substantial growth in receivables, particularly in its Advantage motor finance business [4]